EU/3/19/2174

Table of contents

About

On 28 June 2019, orphan designation EU/3/19/2174 was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for rasagiline for the treatment of Duchenne muscular dystrophy.

Please note that this product was withdrawn from the Union Register of orphan medicinal products in January 2021 on request of the Sponsor.

Key facts

Active substance
rasagiline
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of first decision
28/06/2019
Outcome
Withdrawn
EU designation number
EU/3/19/2174

Sponsor's contact details

TMC Pharma (EU) Limited
The Black Church
St. Mary's Place
Dublin D07 P4AX
Ireland
Tel. +353 76 670 5745
E-mail: regulatory.services@tmcpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating